The health impacts of Chromium Picolinate (CrP) have been searched by various researchers particularly focused on management of Type-2 Diabetes Mellitus (T2DM) with the conflicting results. The objective of the present study was to investigate the role of CrP on management of T2DM. It was a randomized controlled trial (RCT). Two groups of newly diagnosed Type -2 diabetics between the age brackets of 40-65 years were randomly selected from diabetes clinic. One group was exposed to 200 μg of CrP per day and the other was given a capsule of inert material as placebo having no impact on diabetic profile. The intervention duration was 03 months followed by one month as washout period. The outcome variables were biochemistry related to diabetic profile, clinical signs symptoms and toxicity if any. Dietary profile and anthropometrics were used for nutritional assessment. The study revealed that 82.7% of the subjects had family history of diabetes among which 59.6% were close relative. 98.1% were suffering from some kind of stress. Diabetic profile such as FPG, HbA1c and insulin levels improved in terms of normality after three months in treatment group, but did not come to the normal acceptable range e.g. The FPG dropped from142.85±17.71 to 130.42±32.68 mg/dl with a significant P value of 0.003 within the phases. Other health indicators such as lipid profile, blood pressure and clinical signs symptoms also improved and more in treatment group. Dietary counseling showed positive effects on food intake. Renal and hepatic profile showed no signs of toxicity in treatment group. The study concluded that CrP combined with dietary counseling had positive effect on diabetic profile of the newly diagnosed T2DM patients. The clinical signs and symptoms were improved. No hepatic and renal toxicity was observed.